Prostate-specific antigen cut-off point of 2.5 ng/mL and increasing the number of prostate biopsies results in the detection of curable prostate cancer even in Japanese population

International Journal of Urology

Volumn 14, Issue 8, 2007, Pages 709-712

  Saito, Seiichi ^a  

^a Art Park Urology Hospital and Clinic   (Japan)

Author keywords

Prostate cancer; Prostate specific antigen; Saturation biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 34547633279     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01800.x     Document Type: Article

References (18)

1. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991 324 : 1156 61.
2. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer 1997 80 : 1852 6.
3. Catalona WJ, Smith DS, Ratliff TL et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993 270 : 948 54.
4. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of multicenter clinical of 6630 men. J. Urol. 1994 151 : 1283 90.
5. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997 277 : 1452 5.
6. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N. Engl. J. Med. 2004 350 : 2239 46.
7. Epstein JI, Walsh PC, Carmichael M et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 72.
8. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J. Urol. 2001 166 : 86 92.
9. Schroder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 1998 90 : 1817 23.
10. Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cut-off of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002 60 : 469 73.
11. Raaijimakers R, Blijenberg BG, Finlay JA et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/mL: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J. Urol. 2004 171 : 2245 9.
12. Kravchick S, Peled R, Dorfman D et al. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL. Urology 2005 66 : 542 6.
13. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting a PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: a review of 36 3 16 biopsies. Urology 2005 65 : 549 53.
14. Oesterling JE, Jacobson SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993 270 : 860 5.
15. Lowe FC, Cavallo CB, Kahane H. Analysis of 233 9 89 prostate biopsies from 1997 to 2002 confirms the trend of decreasing age of patients undergoing biopsy but does not demonstrate any alteration in the overall detection rate of prostate cancer. J. Urol. 1997 169 : 75.
16. Nadler RB, Loeb SL, Roehl KA et al. Use of 2.6 ng/mL prostate specific antigen prompt for biopsy in men older than 60 years. J. Urol. 2006 174 : 2154 7.
17. Jones JS, Oder M, Zippe CD. Saturation prostate biopsy with periprostatic block can be performed in the office. J. Urol. 2002 168 : 2108 10.
18. Eichler K, Hempel S, Wilby J et al. Diagnostic value of systematic biopsy methods in the investigation of prostatic cancer: a systematic review. J. Urol. 2006 175 : 1605 12.